کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10899649 | 1084399 | 2014 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
Robust Multichip AverageRMAROCSAMRT-PCRDFSSBRFFPE - MEPdisease-free survival - بقاء بدون بیماریSignificance Analysis of Microarrays - تجزیه و تحلیل اهمیت MicroarraysDAVID - دیویدBreast cancer - سرطان پستانformalin-fixed paraffin-embedded - فرمالین ثابت پارافین تعبیه شده استNeoadjuvant - نواجواننتreverse transcription–polymerase chain reaction - واکنش زنجیره ای رونویسی-پلیمراز معکوسPCR - واکنش زنجیرهٔ پلیمرازPathological complete response - واکنش کامل پاتولوژیکResponse to chemotherapy - پاسخ به شیمی درمانیoestrogen receptor - گیرنده استروژنreceiver operating characteristic - گیرنده عامل عاملProgesterone receptor - گیرنده پروژسترون
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
The EndoPredict (EP) signature is a prognostic 11-gene expression signature specifically developed in ER+/HER2- node-negative/positive breast cancer. It is associated with relapse-free survival in patients treated with adjuvant hormone therapy, suggesting that EP low-risk patients could be treated with adjuvant hormone therapy alone whereas high-risk patients would deserve addition of adjuvant chemotherapy. Thus, it is important to determine whether EP high-risk patients are or are not more sensitive to chemotherapy than low-risk patients. Here, we have assessed the EP predictive value for pathological complete response to neoadjuvant chemotherapy in ER+/HER2- breast cancer. We gathered gene expression and histoclinical data of 553 pre-treatment ER+/HER2- breast carcinomas treated with anthracycline-based neoadjuvant chemotherapy. We searched for correlation between the pathological complete response (pCR) and the EP score-based classification. The overall pCR rate was 12%. Fifty-one percent of samples were classified as low-risk according to the EP score and 49% as high-risk. EP classification was associated with a pCR rate of 7% in the low-risk group and 17% in the high-risk group (pâ<â0.001). In multivariate analysis, the EP score remained significantly associated with pCR. Many genes upregulated in the high-risk tumours were involved in cell proliferation, whereas many genes upregulated in the low-risk tumours were involved in ER-signalling and stroma. Despite higher chemosensitivity, the high-risk group was associated with worse disease-free survival. In conclusion, EP high-risk ER+/HER2- breast cancers are more likely to respond to anthracycline-based chemotherapy.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Cancer Letters - Volume 355, Issue 1, 1 December 2014, Pages 70-75
Journal: Cancer Letters - Volume 355, Issue 1, 1 December 2014, Pages 70-75
نویسندگان
François Bertucci, Pascal Finetti, Patrice Viens, Daniel Birnbaum,